Cargando…

Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response

OBJECTIVES: An observational study to evaluate the relationship between serum concentrations of adalimumab and disease activity in patients receiving long-term adalimumab treatment for psoriatic arthritis. METHODS: Serum adalimumab and adalimumab antidrug antibodies were quantified by enzyme linked...

Descripción completa

Detalles Bibliográficos
Autores principales: Chimenti, Maria Sole, Triggianese, Paola, Narcisi, Alessandra, Marinari, Barbara, Teoli, Miriam, Faleri, Sara, Arcese, Annalisa, Perricone, Roberto, Costanzo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536527/
https://www.ncbi.nlm.nih.gov/pubmed/27683139
http://dx.doi.org/10.1177/0300060515593235
_version_ 1783254025197584384
author Chimenti, Maria Sole
Triggianese, Paola
Narcisi, Alessandra
Marinari, Barbara
Teoli, Miriam
Faleri, Sara
Arcese, Annalisa
Perricone, Roberto
Costanzo, Antonio
author_facet Chimenti, Maria Sole
Triggianese, Paola
Narcisi, Alessandra
Marinari, Barbara
Teoli, Miriam
Faleri, Sara
Arcese, Annalisa
Perricone, Roberto
Costanzo, Antonio
author_sort Chimenti, Maria Sole
collection PubMed
description OBJECTIVES: An observational study to evaluate the relationship between serum concentrations of adalimumab and disease activity in patients receiving long-term adalimumab treatment for psoriatic arthritis. METHODS: Serum adalimumab and adalimumab antidrug antibodies were quantified by enzyme linked immunosorbent assay. Disease activity was assessed using Disease Activity Score (44 joint measures). Serum C-reactive protein was quantified using standard methods. RESULTS: A total of 30 patients were recruited. There were significant inverse correlations between serum adalimumab concentration and serum C-reactive protein (CRP) concentration [r = −0.43], the number of tender joints (r = −0.4), and Disease Activity Score (DAS44)-CRP (r = −0.36). Mean serum adalimumab levels were significantly higher in patients with DAS44-CRP <1.6 than in patients with DAS44-CRP ≥1.6. CONCLUSIONS: Serum adalimumab could be an important tool that may improve the management of psoriatic arthritis in patients responding to long-term treatment.
format Online
Article
Text
id pubmed-5536527
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-55365272017-10-03 Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response Chimenti, Maria Sole Triggianese, Paola Narcisi, Alessandra Marinari, Barbara Teoli, Miriam Faleri, Sara Arcese, Annalisa Perricone, Roberto Costanzo, Antonio J Int Med Res Immuno-Mediated Diseases and Treatment Immunogenicity OBJECTIVES: An observational study to evaluate the relationship between serum concentrations of adalimumab and disease activity in patients receiving long-term adalimumab treatment for psoriatic arthritis. METHODS: Serum adalimumab and adalimumab antidrug antibodies were quantified by enzyme linked immunosorbent assay. Disease activity was assessed using Disease Activity Score (44 joint measures). Serum C-reactive protein was quantified using standard methods. RESULTS: A total of 30 patients were recruited. There were significant inverse correlations between serum adalimumab concentration and serum C-reactive protein (CRP) concentration [r = −0.43], the number of tender joints (r = −0.4), and Disease Activity Score (DAS44)-CRP (r = −0.36). Mean serum adalimumab levels were significantly higher in patients with DAS44-CRP <1.6 than in patients with DAS44-CRP ≥1.6. CONCLUSIONS: Serum adalimumab could be an important tool that may improve the management of psoriatic arthritis in patients responding to long-term treatment. SAGE Publications 2016-09-28 2016-09 /pmc/articles/PMC5536527/ /pubmed/27683139 http://dx.doi.org/10.1177/0300060515593235 Text en © The Author(s) 2016 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Immuno-Mediated Diseases and Treatment Immunogenicity
Chimenti, Maria Sole
Triggianese, Paola
Narcisi, Alessandra
Marinari, Barbara
Teoli, Miriam
Faleri, Sara
Arcese, Annalisa
Perricone, Roberto
Costanzo, Antonio
Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
title Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
title_full Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
title_fullStr Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
title_full_unstemmed Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
title_short Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
title_sort long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
topic Immuno-Mediated Diseases and Treatment Immunogenicity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536527/
https://www.ncbi.nlm.nih.gov/pubmed/27683139
http://dx.doi.org/10.1177/0300060515593235
work_keys_str_mv AT chimentimariasole longtermtreatmentwithadalimumabinpsoriaticarthritisserumadalimumabconcentrationimmunogenicityandthelinkwithclinicalresponse
AT triggianesepaola longtermtreatmentwithadalimumabinpsoriaticarthritisserumadalimumabconcentrationimmunogenicityandthelinkwithclinicalresponse
AT narcisialessandra longtermtreatmentwithadalimumabinpsoriaticarthritisserumadalimumabconcentrationimmunogenicityandthelinkwithclinicalresponse
AT marinaribarbara longtermtreatmentwithadalimumabinpsoriaticarthritisserumadalimumabconcentrationimmunogenicityandthelinkwithclinicalresponse
AT teolimiriam longtermtreatmentwithadalimumabinpsoriaticarthritisserumadalimumabconcentrationimmunogenicityandthelinkwithclinicalresponse
AT falerisara longtermtreatmentwithadalimumabinpsoriaticarthritisserumadalimumabconcentrationimmunogenicityandthelinkwithclinicalresponse
AT arceseannalisa longtermtreatmentwithadalimumabinpsoriaticarthritisserumadalimumabconcentrationimmunogenicityandthelinkwithclinicalresponse
AT perriconeroberto longtermtreatmentwithadalimumabinpsoriaticarthritisserumadalimumabconcentrationimmunogenicityandthelinkwithclinicalresponse
AT costanzoantonio longtermtreatmentwithadalimumabinpsoriaticarthritisserumadalimumabconcentrationimmunogenicityandthelinkwithclinicalresponse